Institutional Investors Increase Stakes in Biotech Firm Ocugen

Ocugen US67577C1053

Shares of clinical-stage biopharmaceutical company Ocugen saw elevated trading activity on Monday, with volume running 72% above the average. This coincided with several institutional investors significantly expanding their holdings in the company, which continues to exhibit volatile price movements. Management has stated its cash position is sufficient to fund operations into mid-2026.

Ocugen’s financial results for the third quarter of 2025 presented a mixed picture. The company reported revenue of $1.75 million but posted a loss per share of $0.07, slightly wider than the anticipated loss of $0.06. The net loss for the period amounted to approximately $20 million.